Dr. Lyn Guenther

Dermatologist, London, ON

Dr. Lyn Guenther is a Professor of dermatology at Western University in London Ontario Canada, Fellow of the College of Physicians and Surgeons of Canada (FRCPC) and is Board-Certified in the United States. She received her MD degree from the University of Western Ontario and completed her dermatology residency training at the University of Michigan, Ann Arbor Michigan, USA. She has been involved in more than 190 research projects since 1980 and is the president of Guenther Research Inc.

Dr. Guenther was chair of the Division of Dermatology at Western University from 1991 to 1999 and President of the Canadian Society for Dermatologic Surgery from 2001 to 2003. She chaired the Canadian expert panel for the treatment of moderate-to-severe psoriasis in 2004, was a member of the expert panel for the 2009 and 2016 Canadian Psoriasis Guidelines. She was also a member of the 2015 Canadian Non-melanoma Skin Cancer Guidelines Committee.

Dr. Guenther has more than 200 publications, is a reviewer for a number of journals, and has been the medical editor of Dermatology Times of Canada since 1998. She has lectured to medical students at St. George’s University in Grenada and has acted as an advisor to Health Canada, the Drug Quality and Therapeutics Committee for Ontario, the Canadian Medical Protective Association, the Canadian Cancer Society, and many pharmaceutical companies.

Dr. Guenther enjoys teaching and lectures locally, provincially, nationally and internationally. She has won a certificate of appreciation for excellence in undergraduate medical education and since 2007, has been voted “Best Doctor” by peers. In 2022, she was selected by peers to 2022’s Women in Dermatology Honour Roll.

11:05 AM - 11:50 AM Open Session

Nov 24

2022 recommendations for prevention of shingles in dermatology patients

Learning Objectives:

  • Recognize the clinical manifestations and complications of herpes zoster
  • List risk factors for Zoster and postherpetic neuralgia (PHN)
  • Recognize the benefit of vaccination to prevent zoster and postherpetic neuralgia
  • Discuss when and how to vaccinate your at risk patients against zoster

Summary:
The Canadian lifetime risk for zoster is 28%, and 50% over age 85. In addition to older age, a family history of zoster, immunosuppression and JAK inhibitors can also increase the risk for zoster. Zostavax was the first available zoster vaccine, but it was discontinued in Canada October 14, 2022. Shingrix is a non-live adjuvanted subunit vaccine which has approval for zoster prevention in immunocompetent individuals ≥ 50 years as well as immunocompromised individuals ≥ 18 years. Two doses of 0.5 ml reconstituted Shingrix IM are recommended given 2-6 months apart in immunocompetent individuals and may be given 1-2 months apart in immunocompromised individuals. It is highly efficacious (>90%) in immunocompetent individuals with a minimal decline in clinical efficacy and humoral and cellular immunity over 10 years of follow-up. It addition it has been shown to prevent postherpetic neuralgia and other zoster complications. The efficacy in immunocompromised individuals is comparable with persistent immunity for at least 1 year. Dermatologists should be proactive in recommending vaccination against zoster.